What is the Fiscal Year for Immunovant?
Date: November 13, 2026
Immunovant's current fiscal year starts on April 1, 2026, and ends on March 31, 2027. Their current quarter is Q3, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
April 1, 2026
Fiscal Year End
March 31, 2027
Current Quarter
Q3
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Apr 1, 2026 – Jun 30, 2026
Q2
Jul 1, 2026 – Sep 30, 2026
Q3
Oct 1, 2026 – Dec 31, 2026
Q4
Jan 1, 2027 – Mar 31, 2027
Company Information
Headquarters
Durham, North Carolina, United States
Industry
Biotechnology Research
Stock Symbol
IMVT
Description
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Immunovant and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.